ReviewPhysiological research2025
Platelet Membrane-Camouflaged Biomimetic Drug Delivery Systems for Ischemia-Reperfusion Injury: Targeted Therapeutic Strategies.
Review in Physiological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Nonsurgical Platelet Membrane-Decorated Gold Yarnball Brain Antenna for In Situ Nitric Oxide Generation and Neuronal Regeneration.ACS nano · 2026Article
- ROS-Responsive Nanoparticle Delivery of Dexmedetomidine Protects the Gut Vascular Barrier After Intestinal Ischemia/Reperfusion via the HDAC-H3K27ac-TCF4 Axis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Engineering design of platelet-mimicking therapeutic systems: multilevel biomimicry, gating strategies, and translational boundaries.Frontiers in bioengineering and biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review summarizes the application of platelet membrane-coated biomimetic drug delivery systems in the treatment of various ischemia-reperfusion injuries (I/RI). Platelet membrane-coated nanoparticles, extracellular vesicles, microbubbles, microemulsions, as well as platelet membrane vesicles and their derivatives have shown significant promise for I/RI treatment. By leveraging the specific targeting, adhesive, and immune evasion properties of platelets, these systems enable the targeted delivery of therapeutic agents, such as antioxidants, anti-inflammatory agents, thrombolytics, and neuroprotective compounds, to ischemic tissues, while also offering diagnostic capabilities. However, challenges remain in bridging the gap between research and clinical application, such as scalability, maintaining bioactivity, and potential side effects. Future research should focus on improving scalability, stability, and safety. Furthermore, the context-specific selection or integration of delivery strategies is essential to meet the therapeutic demands of I/RI.
Indexed as
Identifiers
40886365PMC12440380What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.